SUMATRIPTAN SUCCINATE INJECTION

The Defense Logistics Agency awarded a sole-source delivery order to DMS PHARMACEUTICAL GROUP INC under contract number SPE2DP26F7886 for the procurement of one package of SUMATRIPTAN SUCCINATE INJECTION, identified by NSN 6505013745874, at a unit price of $49.84, resulting in a total contract value of $49.84. The award date was July 21, 2026, with delivery required by August 5, 2026, to the designated destination at Fort Stewart, Georgia, under FOB destination terms, meaning the contractor bears all transportation costs and responsibilities until physical receipt by the government at the delivery point. The item is sourced from a manufacturer with CAGE code 34006, and the awardee’s CAGE code is 1UNB0, aligning with federal supply chain protocols. No option periods, quantity variance, or additional line items are included, and the award reflects a fixed-quantity, fixed-price transaction with no flexibility in delivery volume. Packaging and marking requirements specify the use of traceable shipping methods excluding parcel post, with mandatory labeling including the mark-for address, TCN W33RBS62010728, and RDD 213, though no MIL-STD packaging standards, bar-code specifications, or preservation details are provided. Inspection and acceptance occur at the destination, with the contractor responsible for compliance and delivery performance. No FAR or DFARS clauses, evaluation factors, representations, certifications, special requirements, or payment office details are documented in the award materials, indicating a minimalistic delivery order structured for rapid execution of a single pharmaceutical item. No contracting officer, COR, COTR, or invoice processing instructions are named, and accounting codes such as TAS or AAC are not referenced, despite the use of PR number 7017577704. The procurement was processed under DLA’s standard logistics framework, leveraging NSN and CAGE code systems, without the inclusion of socioeconomic certifications, size status declarations, or regulatory compliance affirmations beyond basic identification.